HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IL-20 and IL-20R1 antibodies protect against liver fibrosis.

AbstractUNLABELLED:
Interleukin (IL)-20 is a proinflammatory cytokine of the IL-10 family and involved in rheumatoid arthritis, atherosclerosis, stroke, and osteoporosis. However, the pathophysiological roles of IL-20 in liver injury have not been extensively studied. We explored the involvement of IL-20 in liver injury and the therapeutic potential of IL-20 antagonists for treating liver fibrosis. Compared with normal liver tissue from healthy individuals, the amount of IL-20 was much higher in hepatocytes and hepatic stellate cells in liver biopsies from patients with fibrosis, cirrhosis, and hepatocellular carcinoma. Carbon tetrachloride (CCl4) treatment induced IL-20 that further up-regulated the expression of transforming growth factor (TGF)-β1 and p21(WAF1) and resulted in cell cycle arrest in the Clone-9 rat hepatocyte cell line. IL-20 activated quiescent rat hepatic stellate cells (HSCs) and up-regulated TGF-β1 expression. IL-20 also increased TGF-β1, tumor necrosis factor (TNF)-α, and type I collagen (Col-I) expression, and promoted the proliferation and migration of activated HSCs. Serum IL-20 was significantly elevated in mice with short-term and long-term CCl4 -induced liver injury. In mice with short-term liver injury, anti-IL-20 monoclonal antibody (7E) and anti-IL-20 receptor (IL-20R1) monoclonal antibody (51D) attenuated hepatocyte damage caused by CCl4, TGF-β1, and chemokine production. In mice with long-term liver injury, 7E and 51D inhibited CCl4 -induced cell damage, TGF-β1 production, liver fibrosis, HSC activation, and extracellular matrix accumulation, which was caused by the reduced expression of tissue inhibitors of metalloproteinases as well as increased metalloproteinase expression and Col-I production. IL-20R1-deficient mice were protected from short-term and long-term liver injury.
CONCLUSION:
We identified a pivotal role of IL-20 in liver injury and showed that 7E and 51D may be therapeutic for liver fibrosis.
AuthorsYi-Shu Chiu, Chi-Chen Wei, Yih-Jyh Lin, Yu-Hsiang Hsu, Ming-Shi Chang
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 60 Issue 3 Pg. 1003-14 (Sep 2014) ISSN: 1527-3350 [Electronic] United States
PMID24763901 (Publication Type: Journal Article)
Copyright© 2014 by the American Association for the Study of Liver Diseases.
Chemical References
  • Antibodies, Monoclonal
  • Interleukins
  • Receptors, Interleukin
  • interleukin-20 receptor
  • interleukin 20
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Carbon Tetrachloride Poisoning (complications, metabolism)
  • Case-Control Studies
  • Cell Line
  • Chemical and Drug Induced Liver Injury (complications, metabolism)
  • Disease Models, Animal
  • Humans
  • Interleukins (antagonists & inhibitors, immunology, metabolism)
  • Liver Cirrhosis (etiology, immunology, metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Interleukin (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: